April 29, 2016Open Access
View Full PaperA randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Structured PICO
Does finerenone reduce NT-proBNP levels and clinical events compared to eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease?
P
Population
Patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
I
Intervention
Finerenone (including a 10 to 20 mg dose group)
C
Comparator
Eplerenone
O
Outcome
30% or greater decrease in NT-proBNP levelssurrogate
Finerenone is well tolerated and similarly effective to eplerenone in reducing NT-proBNP in patients with worsening chronic heart failure and diabetes or CKD.
Abstract
Finerenone was well tolerated and induced a 30% or greater decrease in NT-proBNP levels in a similar proportion of patients to eplerenone. The finding of reduced clinical events in the finerenone 10→20 mg group should be further explored in a large outcomes trial.